Category: Blood / Hematology

DKMS, the world’s largest bone marrow donor center, and The Leukemia & Lymphoma Society’s New York City Chapter will team up at this year’s Light The Night Walk(R) to pay homage to patients battling cancer and to recruit bone […]

Archimedes Pharma UK Limited, the UK based, pan-European specialty pharmaceutical company, announces the launch of Zibor® (bemiparin sodium) to the UK market. A second-generation low molecular weight heparin (LMWH), Zibor is the only LMWH licensed in the UK for post-operative initiation of thromboprophylaxis in any patients undergoing orthopaedic and general surgery. Already used by over […]

Genmab A/S (OMX: GEN) announced it has completed recruitment of patients in the pivotal Phase III study of ofatumumab (HuMax-CD20(R)) in rituximab refractory follicular non-Hodgkin’s lymphoma (NHL). Eighty-one patients receiving treatment at the 1000 mg dose level of ofatumumab have […]

Clinicians and patient groups have welcomed today’s announcement by the National Institute of Health and Clinical Excellence (NICE) recommending Pradaxa(R) (dabigatran etexilate) as an option for the primary prevention of venous thrombembolic events in adults who have undergone elective total hip […]

Maisonneuve-Rosemont Hospital (MRH), which is affiliated to the Université de Montréal, plans to open the Centre d’excellence en thérapie cellulaire (CETC) in 2010. The CETC will focus on stem cell research, regenerative medicine and different types of blood cancers. “Our hope is to have a world class hemo-oncology center such as the […]

AdvanDx announced it received FDA 510(k) clearance of the Yeast Traffic Light PNA FISH™ to identify Candida yeast species directly from positive blood cultures. The Yeast Traffic Light™ is the latest addition to AdvanDx’s easy-to-use, molecular-based PNA FISH™ diagnostics platform that provides rapid identification of bloodstream pathogens in hours instead of days.

Share […]

The Beaumont Commercialization Center, a medical device development company within Beaumont Hospitals, has a new surgical instrument available for licensing. Paul J. Arpasi, M.D., a Beaumont radiologist, developed a device that will help reduce the risk for […]

AVEO Pharmaceuticals, Inc., announced that it has initiated a Phase 1 clinical trial to evaluate the safety, tolerability and recommended dose of SCH900105 (AV-299), its novel, highly potent antibody to hepatocyte growth factor (HGF), administered intravenously in patients with relapsed or refractory solid tumors or lymphoma. SCH900105 (AV-299) is being developed in collaboration with Schering-Plough […]

PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a Phase I clinical study in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. […]

AVEO Pharmaceuticals, Inc., announced that it has initiated a Phase 1 clinical trial to evaluate the safety, tolerability and recommended dose of SCH900105 (AV-299), its novel, highly potent antibody to hepatocyte growth factor (HGF), administered intravenously in patients with relapsed or refractory solid tumors or lymphoma. SCH900105 (AV-299) is being developed in collaboration with Schering-Plough […]